How to nurture natural products to create new therapeutics: Strategic innovations and molecule-to-medicinal insights into therapeutic advancements.

IF 6.5 2区医学 Q1 PHARMACOLOGY & PHARMACY

Drug Discovery Today Pub Date : 2024-10-29 DOI:10.1016/j.drudis.2024.104221

Ayan Acharya, Mithilesh Nagpure, Nibedita Roy, Vaibhav Gupta, Soumyadeep Patranabis, Sankar K Guchhait

{"title":"How to nurture natural products to create new therapeutics: Strategic innovations and molecule-to-medicinal insights into therapeutic advancements.","authors":"Ayan Acharya, Mithilesh Nagpure, Nibedita Roy, Vaibhav Gupta, Soumyadeep Patranabis, Sankar K Guchhait","doi":"10.1016/j.drudis.2024.104221","DOIUrl":null,"url":null,"abstract":"<p><p>Natural products (NPs) are privileged structures interacting with biomacromolecular targets and exhibiting biological effects important for human health. In this review, we have presented NP-inspired strategic innovations that are promising for addressing preclinical and clinical challenges. An analysis of 'molecule-to-medicinal' properties for improvement of P3 and absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles has been illustrated. The strategies include chemical evolution through knowledge of structure-medicinal properties, truncation of NPs to avoid molecular obesity, pseudo-NPs, selection of common structural features of NPs, medicinophore installation, scaffold hopping, and induced proximity. Molecule-to-medicinal property analysis can guide the development of 'nature-to-new' chemical therapeutics. Coupled with scientific advances and innovations in instrumentation, these strategies hold great potential for enhancing drug design and discovery.</p>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":null,"pages":null},"PeriodicalIF":6.5000,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.drudis.2024.104221","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Natural products (NPs) are privileged structures interacting with biomacromolecular targets and exhibiting biological effects important for human health. In this review, we have presented NP-inspired strategic innovations that are promising for addressing preclinical and clinical challenges. An analysis of 'molecule-to-medicinal' properties for improvement of P3 and absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles has been illustrated. The strategies include chemical evolution through knowledge of structure-medicinal properties, truncation of NPs to avoid molecular obesity, pseudo-NPs, selection of common structural features of NPs, medicinophore installation, scaffold hopping, and induced proximity. Molecule-to-medicinal property analysis can guide the development of 'nature-to-new' chemical therapeutics. Coupled with scientific advances and innovations in instrumentation, these strategies hold great potential for enhancing drug design and discovery.

查看原文本刊更多论文

如何培育天然产品以创造新疗法：战略创新和从分子到药物的治疗进展见解。

天然产物（NPs）是与生物分子靶点相互作用的特殊结构，对人类健康具有重要的生物效应。在这篇综述中，我们介绍了受 NP 启发的战略创新，这些创新在应对临床前和临床挑战方面大有可为。我们分析了 "从分子到药物 "的特性，以改善 P3 以及吸收、分布、代谢、排泄和毒性（ADMET）特征。这些策略包括通过了解结构-药用特性实现化学进化、截短 NPs 以避免分子肥胖、伪 NPs、选择 NPs 的共同结构特征、安装药用发泡体、支架跳跃和诱导接近。从分子到药物的特性分析可以指导 "从自然到新 "化学疗法的开发。这些策略与科学进步和仪器创新相结合，在加强药物设计和发现方面具有巨大潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Discovery Today 医学-药学

CiteScore

14.80

自引率

2.70%

发文量

293

审稿时长

6 months

期刊介绍： Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed. Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.